A JAMA case report connected amyloid clearance to downstream neuropathologic change after amyloid-targeting therapy in Alzheimer’s disease. The report described cases where regions showing extensive amyloid removal also demonstrated reduced subsequent neuropathologic alterations, supporting a relationship between amyloid burden reduction and disease progression. While case-level evidence cannot establish causality, the findings add to the body of post-treatment pathology observations that regulators and clinicians increasingly weigh when interpreting biomarker-to-clinical links.